{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T07:27:57Z","timestamp":1771399677999,"version":"3.50.1"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the effects of 3C4L vs. 2C3L radiofrequency ablation strategies on quantitative myocardial motion parameters and serum biomarkers in patients with persistent atrial fibrillation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A retrospective study was conducted on 105 patients with persistent atrial fibrillation who underwent radiofrequency ablation treatment at our hospital between March 2023 and November 2024. All patients' data were obtained from the medical record system. Patients were divided into two groups based on the ablation strategy employed: a 2C3L group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200950, two circumferential lesions plus three linear lesions) and a 3C4L group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200955, three circumferential lesions plus four linear lesions). The choice of ablation strategy was determined by the treating physician based on atrial fibrillation characteristics, left atrial size, and institutional experience during the study period. Clinical baseline data, perioperative related indexes, quantitative myocardial exercise parameters, and serum biomarkers were compared between the two groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There was no statistically significant difference in circumferential pulmonary vein isolation ablation time, cavotricuspid isthmus ablation time, and left atrial apical line ablation time between the 3C4L group and the 2C3L group (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;gt;\u20090.05). However, the 3C4L group had significantly longer total procedure time (172.06\u2009\u00b1\u200939.33 vs. 156.10\u2009\u00b1\u200936.37\u2005min,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.034), mitral isthmus ablation time (14.58\u2009\u00b1\u20092.78 vs. 10.21\u2009\u00b1\u20092.96\u2005min,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001), X-ray exposure time (7.05\u2009\u00b1\u20091.87 vs. 2.60\u2009\u00b1\u20090.42\u2005min,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001), and greater saline perfusion volume (1,197.43\u2009\u00b1\u2009184.47 vs. 1,072.33\u2009\u00b1\u200957.42\u2005mL,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001) compared to the 2C3L group. Before treatment, there were no significant differences between groups in quantitative myocardial motion parameters and serum biomarker indexes (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;gt;\u20090.05). After treatment, the 3C4L group showed significantly better improvement in quantitative myocardial motion parameters and serum biomarker indexes compared to the 2C3L group (all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05). The total incidence rate of complications was not significantly different between the 3C4L group (20.00%, 11\/55) and the 2C3L group (16.00%, 8\/50) (\n                      <jats:italic>\u03c7<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090.575,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.448). At 24 months, Kaplan\u2013Meier analysis demonstrated significantly higher arrhythmia-free survival in the 3C4L group compared to the 2C3L group (50.0% vs. 30.0%, log-rank\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.018; hazard ratio 0.52, 95% confidence interval: 0.30\u20130.90).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Compared with the 2C3L radiofrequency ablation strategy, the 3C4L strategy, while requiring longer procedure time, does not significantly increase complication rates and demonstrates superior clinical efficacy with better improvement in cardiac function and long-term arrhythmia-free survival. These findings should be interpreted cautiously given the retrospective, non-randomized study design and require validation through prospective randomized controlled trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2025.1591569","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T06:54:19Z","timestamp":1771397659000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of 3C4L and 2C3L radiofrequency ablation strategies for persistent atrial fibrillation: procedural profile and 2-year outcomes"],"prefix":"10.3389","volume":"12","author":[{"given":"Pengcheng","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine 3, Dongzhimen Hospital, Beijing University of Traditional Chinese Medicine","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine 3, Dongzhimen Hospital, Beijing University of Traditional Chinese Medicine","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongyi","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine 3, Dongzhimen Hospital, Beijing University of Traditional Chinese Medicine","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine 4, Dongzhimen Hospital, Beijing University of Traditional Chinese Medicine","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine 3, Dongzhimen Hospital, Beijing University of Traditional Chinese Medicine","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1159\/000528758","article-title":"Indirect comparison of cryoablation and radiofrequency ablation as initial therapy for symptomatic paroxysmal atrial fibrillation: a systematic review and network meta-analysis of randomized controlled trials","volume":"148","author":"Mao","year":"2023","journal-title":"Cardiology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/jce.15831","article-title":"Network meta-analysis and systematic review comparing efficacy and safety between very high power short duration, high power short duration, and conventional radiofrequency ablation of atrial fibrillation","volume":"34","author":"Tokavanich","year":"2023","journal-title":"J Cardiovasc Electrophysiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e20230091","DOI":"10.36660\/abc.20230091","article-title":"Chasing new non-invasive parameters to predict atrial fibrillation after radiofrequency catheter ablation","volume":"120","author":"Lima-Concei\u00e7\u00e3o","year":"2023","journal-title":"Arq Bras Cardiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1111\/jce.14676","article-title":"A systematic review and meta-analysis comparing second-generation cryoballoon and contact force radiofrequency ablation for initial ablation of paroxysmal and persistent atrial fibrillation","volume":"31","author":"Ravi","year":"2020","journal-title":"J Cardiovasc Electrophysiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1016\/j.hrthm.2024.04.098","article-title":"Catheter ablation for atrial fibrillation in heart failure with reduced ejection fraction patients: a meta-analysis","volume":"21","author":"Pasqualotto","year":"2024","journal-title":"Heart Rhythm"},{"key":"B6","doi-asserted-by":"publisher","first-page":"oeae058","DOI":"10.1093\/ehjopen\/oeae058","article-title":"Catheter ablation for atrial fibrillation and impact on clinical outcomes","volume":"4","author":"Providencia","year":"2024","journal-title":"Eur Heart J Open"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.7326\/ANNALS-25-00253","article-title":"Catheter and surgical ablation for atrial fibrillation: a systematic review and meta-analysis","volume":"178","author":"Montan\u00e9","year":"2025","journal-title":"Ann Intern Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2025.05.021","article-title":"Ablation of atrial fibrillation and risk of stroke: a meta-analysis","author":"Providencia","year":"2025","journal-title":"Heart Rhythm"},{"key":"B9","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.ccep.2020.02.003","article-title":"Recurrent atrial fibrillation after radiofrequency ablation: what to expect","volume":"12","author":"Cherian","year":"2020","journal-title":"Card Electrophysiol Clin"},{"key":"B10","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41569-020-00451-x","article-title":"Catheter ablation for atrial fibrillation: current indications and evolving technologies","volume":"18","author":"Parameswaran","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00399-021-00836-6","article-title":"Late arrhythmia recurrence after atrial fibrillation ablation: incidence, mechanisms and clinical implications","volume":"33","author":"Erhard","year":"2022","journal-title":"Herzschrittmacherther Elektrophysiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"659","DOI":"10.2217\/cer-2021-0170","article-title":"Atrial fibrillation ablation with advanced radiofrequency catheter versus second-generation cryoballoon catheter","volume":"11","author":"Berman","year":"2022","journal-title":"J Comp Eff Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1093\/europace\/euaa327","article-title":"High-power short duration vs. conventional radiofrequency ablation of atrial fibrillation: a systematic review and meta-analysis","volume":"23","author":"Ravi","year":"2021","journal-title":"Europace"},{"key":"B14","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1186\/s12872-020-01635-6","article-title":"Prognostic value of heart failure echocardiography index in HF patients with preserved, mid-ranged and reduced ejection fraction","volume":"20","author":"Chen","year":"2020","journal-title":"BMC Cardiovasc Disord"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1143458","DOI":"10.3389\/fendo.2023.1143458","article-title":"Serum uric acid: a risk factor for right ventricular dysfunction and prognosis in heart failure with preserved ejection fraction","volume":"14","author":"Deng","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"9826484","DOI":"10.34133\/2022\/9826484","article-title":"Electrochemical evaluation of tumor development via cellular interface supported CRISPR\/Cas trans-cleavage","volume":"2022","author":"Cheng","year":"2022","journal-title":"Research (Wash D C)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e035695","DOI":"10.1161\/JAHA.124.035695","article-title":"Catheter ablation or surgical therapy in severe atrial functional mitral regurgitation caused by long-standing persistent atrial fibrillation-propensity score analysis","volume":"13","author":"Ye","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"B18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ahj.2023.01.019","article-title":"Prospective randomized comparison between upgraded \u20182C3L\u2019 vs. PVI approach for catheter ablation of persistent atrial fibrillation: PROMPT-AF trial design","volume":"260","author":"Liu","year":"2023","journal-title":"Am Heart J"},{"key":"B19","doi-asserted-by":"publisher","first-page":"726967","DOI":"10.3389\/fendo.2021.726967","article-title":"COVID-19 and obesity: role of ectopic visceral and epicardial adipose tissues in myocardial injury","volume":"12","author":"Lasbleiz","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.121.057095","article-title":"Randomized ablation-based rhythm-control versus rate-control trial in patients with heart failure and atrial fibrillation: results from the RAFT-AF trial","volume":"145","author":"Parkash","year":"2022","journal-title":"Circulation"},{"key":"B21","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1186\/s13019-024-02742-7","article-title":"Model for predicting the recurrence of atrial fibrillation after monopolar or bipolar radiofrequency ablation in patients with AF and mitral valve disease","volume":"19","author":"Si","year":"2024","journal-title":"J Cardiothorac Surg"},{"key":"B22","doi-asserted-by":"publisher","first-page":"995838","DOI":"10.3389\/fnut.2022.995838","article-title":"Lowering serum homocysteine in H-type hypertensive patients with atrial fibrillation after radiofrequency catheter ablation to prevent atrial fibrillation recurrence","volume":"9","author":"Dong","year":"2022","journal-title":"Front Nutr"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1111\/pace.14595","article-title":"Repeat ablation strategy for recurrent persistent atrial fibrillation: a propensity-matched score comparison between \u201c2C3L\u201d and \u201cextensive ablation\u201d approach","volume":"45","author":"Lin","year":"2022","journal-title":"Pacing Clin Electrophysiol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.jacep.2022.10.019","article-title":"Very high-power short-duration, temperature-controlled radiofrequency ablation in paroxysmal atrial fibrillation: the prospective multicenter Q-FFICIENCY trial","volume":"9","author":"Osorio","year":"2023","journal-title":"JACC Clin Electrophysiol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.jacep.2023.02.003","article-title":"Prophylactic colchicine after radiofrequency ablation of atrial fibrillation: the PAPERS study","volume":"9","author":"Ahmed","year":"2023","journal-title":"JACC Clin Electrophysiol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s10840-023-01651-4","article-title":"Pulsed-field vs. cryoballoon vs. radiofrequency ablation: a propensity score matched comparison of one-year outcomes after pulmonary vein isolation in patients with paroxysmal atrial fibrillation","volume":"67","author":"Maurhofer","year":"2024","journal-title":"J Interv Card Electrophysiol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/s11886-023-01968-6","article-title":"Index-guided high-power radiofrequency catheter ablation for atrial fibrillation: a systematic review and meta-analysis study","volume":"25","author":"Waranugraha","year":"2023","journal-title":"Curr Cardiol Rep"},{"key":"B28","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1177\/02184923231200518","article-title":"Radiofrequency ablation of atrial fibrillation: a 14 years\u2019 experience at a tertiary care center in Thailand","volume":"31","author":"Tokavanich","year":"2023","journal-title":"Asian Cardiovasc Thorac Ann"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1591569\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T06:54:20Z","timestamp":1771397660000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1591569\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":28,"alternative-id":["10.3389\/fcvm.2025.1591569"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2025.1591569","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]},"article-number":"1591569"}}